 |
 |
Source: Datamonitor NewsWire October 13, 2004 HEADLINE: Positive trial results for Schwarz's Parkinson's patch Schwarz Pharma has announced that its Neupro patch significantly reduced 'off ' time in advanced Parkinson's disease patients when used as an adjunctive therapy. Results of the study showed, that both primary endpoints for the US and Europe were achieved and the product appeared to be well tolerated. In the US phase III trial Neupro (rotigotine transdermal system) was added to stable levodopa treatment for 351 patients with advanced stage idiopathic Parkinson's disease. Responses showed a statistically significant and clinically relevant reduction in 'off' time without an increase in undesirable dyskinesias. The most common adverse events associated with the use of rotigotine transdermal system are application site reactions, somnolence, nausea and dizziness. "This trial demonstrates that Neupro in adjunctive therapy with patients with advanced stage Parkinson's disease can be efficacious, tolerable and safe," said Iris Loew-Friedrich, MD, PhD, Member of the Executive Board Schwarz Pharma AG. The European phase III trial with Neupro as adjunctive therapy in patients with advanced stage Parkinson's disease started in the second quarter of 2004, with results expected early in 2006. Neupro, which contains the active ingredient rotigotine, is a novel dopamine receptor-agonist formulated as a patch. It is applied once a day to the skin and administers rotigotine transdermally to the body for 24 hours. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn